8月19日，生物科技指数ETF-iShares Nasdaq（IBB）盘中上涨5.1%，报213.88美元，成交额1.03亿美元。
消息面上，生物科技板块近期迎来多重利好共振。一方面，跨国药企（MNC）并购进入加速期，受专利悬崖驱动，截至8月7日已发生45起MNC收并购交易，已披露总交易金额达1179.5亿美元，肿瘤、自免及神经领域交易升温明显；Argenx正式发起对Forte Biosciences的要约收购，同时其Vyvgart Hytrulo被认为有望获FDA批准用于肌炎治疗。另一方面，AI制药订单持续落地驱动生命科学上游需求攀升，板块整体景气度回暖。此外，再生元Libtayo获加拿大卫生部批准用于高危皮肤鳞状细胞癌辅助治疗，进一步提振市场情绪。
该ETF追踪纳斯达克生物医疗指数，包含在纳斯达克上市的生物医疗公司，成分和权重可能随时间变化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.